Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer



Status:Recruiting
Conditions:Lung Cancer, Lung Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:3/31/2019
Start Date:May 24, 2016
End Date:September 30, 2021
Contact:Use link at the bottom of the page to see if you qualify for an enrolling site (see list). If you still have questions:
Email:JNJ.CT@sylogent.com

Use our guide to learn which trials are right for you!

A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects With Advanced Non-Small Cell Lung Cancer

The purpose of this study is to evaluate the safety and pharmacokinetics, establish a
recommended phase 2 dose (RP2D) regimens, and to assess the preliminary efficacy of
JNJ-61186372 in participants with advanced non-small cell lung cancer (NSCLC).

This open label (all participants know the identity of the study drug), multicenter (more
than one study site), first-in-human study consists of 2 parts. Part 1 is a dose escalation
and Part 2 is a dose expansion cohort. In Part 1, participants with evaluable non-small cell
lung cancer (NSCLC) will be enrolled into cohorts at increasing dose levels of JNJ-61186372,
which will be administered in 28 day treatment cycles. The dose will be escalated until the
maximum tolerated dose (MTD, or maximum administered dose [MAD], if no MTD is found) is
reached. Part 1 will follow a traditional 3+3 design. At each dose level, 3 participants will
complete Cycle 1. If no dose limiting toxicity (DLT) occurs in these 3 participants, then
escalation will continue in a new cohort of 3 participants. Data from Part 1 will be used to
determine one or more recommended phase 2 dose (RP2D) regimen(s). In Part 2, participants
with documented epidermal growth factor receptor (EGFR) mutations and measurable disease,
whose disease has progressed after previous treatment will be enrolled and receive
JNJ-61186372 at the RP2D determined in Part 1. For both parts, the study consists of 3
periods: a Screening period (up to 28 days prior to the first dose of study drug); a
Treatment period (first dose of study drug until 30 days after the last dose of study drug);
and a Follow Up period (approximately 6 months). All participants will be followed for
survival in the post-treatment follow-up period until the end of study and safety will be
monitored throughout the study.

Inclusion Criteria:

- Participant must have histologically or cytologically confirmed non-small cell lung
cancer (NSCLC) that is metastatic or unresectable. Participants must have either
progressed after receiving prior therapy for metastatic disease, or be ineligible for,
or have refused all other currently available therapeutic options

- For Part 2 only: Participants must also have disease with a previously diagnosed
activating epidermal growth factor receptor (EGFR) mutation (includes both inhibitor
sensitive primary mutations such as Exon 19 deletion and L858R [Cohort C], as well as
marketed tyrosine kinase inhibitor [TKI] -resistant mutations such as Exon 20
insertion [Cohort C and D]). Documentation of EGFR mutation eligibility by
CLIA-certified laboratory (or equivalent) testing is required

- For Part 1: Participant must have evaluable disease. For Part 2: Participant must have
measurable disease according to Response Criteria in Solid Tumors (RECIST) v1.1

- For Part 2: Cohort A and B: Participants disease must have most recently progressed
following treatment with a marketed EGFR inhibitor. Exception: In participants
diagnosed with mutations associated with de novo EGFR inhibitor resistance (for
example, exon 20 insertions), only previous treatment with combination platinum-based
chemotherapy is required. Cohort C: Participants must have documented EGFR or
mesenchymal-epithelial transition (cMET) alterations mediating resistance to previous
treatment with a third generation TKI (for example, osimertinib), or in the case of
primary Exon 20ins disease, previous treatment with a TKI with known activity against
Exon 20ins disease (for example, poziotinib). Cohort D: Participants must have been
previously diagnosed with an EGFR Exon 20 insertion

- Participant must have Eastern Cooperative Oncology Group (ECOG) performance status 0
or 1

Exclusion Criteria:

- Participant has uncontrolled inter-current illness, including but not limited to
poorly controlled hypertension, other cardiovascular disease, or diabetes, ongoing or
active infection, or psychiatric illness/social situation that would limit compliance
with study requirements

- Participant has had prior chemotherapy, targeted cancer therapy, immunotherapy, or
treatment with an investigational anticancer agent within 2 weeks or 4 half-lives
whichever is longer, before the first administration of JNJ-61186372. For agents with
long half-lives, the maximum required time since last dose is 4 weeks. Toxicities from
previous anticancer therapies should have resolved to baseline levels or to Grade 1 or
less, (except for alopecia [any grade], Grade less than or equal to [<=] 2 peripheral
neuropathy, and Grade less than [<] 2 hypothyroidism stable on hormone replacement).
For Part 2 only: Cohorts A and B: Prior treatment with chemotherapy for metastatic
disease is not allowed unless the tumor mutation carries de-novo resistance to EGFR
tyrosine kinase inhibitor (TKI) (eg, exon 20 insertions). Cohort C: Prior treatment
with more than 2 lines of cytotoxic chemotherapy for metastatic disease (maintenance
therapy is not included). Cohort D: Previous treatment with an EGFR TKI with activity
against EGFR Exon 20 insertions (such as poziotinib)

- Participants with untreated brain metastases. Participants with treated metastases
that are clinically stable and asymptomatic for at least 2 weeks and who are off or
receiving low-dose corticosteroid treatment (<=10 mg prednisone or equivalent) for at
least 2 weeks prior to study treatment are eligible

- Participant has a history of malignancy other than the disease under study within 3
years before Screening (exceptions are squamous and basal cell carcinomas of the skin
and carcinoma in situ of the cervix, or malignancy that in the opinion of the
investigator, with concurrence with the sponsor's medical monitor, is considered cured
with or minimal risk of recurrence within a year from screening)

- Participant has not fully recovered from major surgery or significant traumatic injury
prior the first dose of study drug or expects to have major surgery during the study
period or within 6 months after the last dose of study drug
We found this trial at
19
sites
?
mi
from
Tampa, FL
Click here to add this to my saved trials
5801 South Ellis Avenue
Chicago, Illinois 60637
 773.702.1234
University of Chicago One of the world's premier academic and research institutions, the University of...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
4805 Northeast Glisan Street
Portland, Oregon 97213
(503) 215-1111
Providence Portland Medical Center We strive to give those we serve exceptional, compassionate health care...
?
mi
from
Portland, OR
Click here to add this to my saved trials
1500 East Medical Center Drive
Ann Arbor, Michigan 48109
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
1365 Clifton Rd NE
Atlanta, Georgia 30322
(404) 778-1900
Winship Cancer Institute at Emory University Winship Cancer Institute of Emory University is Georgia
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
119-143 Missenden Road
Camperdown, 2050
?
mi
from
Camperdown,
Click here to add this to my saved trials
Duarte, California 91010
?
mi
from
Duarte, CA
Click here to add this to my saved trials
8503 Arlington Blvd., Ste. 400
Fairfax, Virginia 22031
(703) 280-5390
Virginia Cancer Specialists, PC Now the world's most advanced cancer treatment capabilities can be found...
?
mi
from
Fairfax, VA
Click here to add this to my saved trials
3855 Health Sciences Dr,
La Jolla, California 92093
(858) 822-6100
UC San Diego Moores Cancer Center Established in 1978, UC San Diego Moores Cancer Center...
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
10833 Le Conte Ave
Los Angeles, California 90095
(310) 825-4321
David Geffen School of Medicine, UCLA In 2002 Mr. David Geffen announced a $200 million...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
New York, New York 10029
?
mi
from
New York, NY
Click here to add this to my saved trials
630 W 168th St
New York, New York
212-305-2862
Columbia University Medical Center Situated on a 20-acre campus in Northern Manhattan and accounting for...
?
mi
from
New York, NY
Click here to add this to my saved trials
Orange, California 92868
?
mi
from
Orange, CA
Click here to add this to my saved trials
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Rochester, Minnesota 55905
?
mi
from
Rochester, MN
Click here to add this to my saved trials
660 S Euclid Ave
Saint Louis, Missouri 63110
(314) 362-5000
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
?
mi
from
West Hollywood, CA
Click here to add this to my saved trials